(Q34272763)

1 August 2017

title

Janus kinases: an ideal target for the treatment of autoimmune diseases. (English)

1 reference

1 August 2017

Massimo Gadina

1

1 reference

1 August 2017

publication date

1 December 2013

1 reference

The journal of investigative dermatology. Symposium proceedings

1 August 2017

published in

1 reference

1 August 2017

volume

16

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

S70-2

1 reference

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4181323

Cytokine signaling: birth of a pathway

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4181323

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4181323

Genome-wide association studies: a new window into immune-mediated diseases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4181323

A quantitative analysis of kinase inhibitor selectivity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4181323

Biologic therapies in rheumatology: lessons learned, future directions

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4181323

A gain-of-function mutation of JAK2 in myeloproliferative disorders

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4181323

Jaks and STATs: biological implications

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4181323

Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4181323

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24326567

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24326567

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/JIDSYMP.2013.29

1 reference

1 August 2017

1 reference

1 August 2017

1 reference